| Advancing 89Zr-immuno-PET in neuroscience with a bispecific anti-amyloid-beta monoclonal antibody-The choice of chelator is essential TE Wuensche, N Stergiou, I Mes, M Verlaan, M Schreurs, EJM Kooijman, ... Theranostics 12 (16), 7067, 2022 | 18 | 2022 |
| Application of 89Zr-DFO*-immuno-PET to assess improved target engagement of a bispecific anti-amyloid-ß monoclonal antibody N Stergiou, TE Wuensche, M Schreurs, I Mes, M Verlaan, EJM Kooijman, ... European journal of nuclear medicine and molecular imaging 50 (5), 1306-1317, 2023 | 15 | 2023 |
| Good practices for 89Zr radiopharmaceutical production and quality control TE Wuensche, S Lyashchenko, GAMS van Dongen, D Vugts EJNMMI Radiopharmacy and Chemistry 9 (1), 40, 2024 | 5 | 2024 |
| Radiolabelled cyclic bisarylmercury: high chemical and in vivo stability for theranostics IMF Gilpin, M Ullrich, T Wünsche, K Zarschler, O Lebeda, J Pietzsch, ... ChemMedChem 16 (17), 2645-2649, 2021 | 3 | 2021 |
| New prospects for 89Zr-immuno-PET in brain applications–alpha-synucleinopathies TE Wuensche, PM Pereira, AD Windhorst, K Bjerregaard-Andersen, ... Nuclear Medicine and Biology 140, 108969, 2025 | 1 | 2025 |
| Investigation of the Impact of the H310A FcRn Region Mutation on 89Zr-Immuno-PET Brain Imaging with a BBB-Shuttle Anti‑Amyloid Beta Antibody TE Wuensche, N Stergiou, I Mes, M Verlaan, EJM Kooijman, ... Molecular Imaging and Biology 26 (5), 823-834, 2024 | 1 | 2024 |
| Development of Zr-89-antibody-PET imaging to evaluate improved brain targeting via transferrin receptor 1: the chelator matters T Wuensche, N Stergiou, I Mes, M Verlaan, M Schreurs, E Kooijman, ... Nuclear medicine and biology 108, S24-S24, 2022 | 1 | 2022 |
| 89Zr-Immuno-PET as an alternative to radioiodinated bispecific BBB-shuttles targeting alpha-synuclein in a murine seeding model. T Wuensche, P Pereira, A Windhorst, K Bjerregaard-Andersen, F Sotty, ... EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 51, S435-S436, 2024 | | 2024 |
| Brain Pretargeted PET–New Horizons to Image CNS Targets with Monoclonal Antibodies T Gustavsson, T Kustermann, L Hvass, V Shalgunov, AS Clausen, S Stotz, ... bioRxiv, 2024.10. 12.617694, 2024 | | 2024 |
| Improving Routine 89Zr‐Immuno‐PET Applications: Mild Iron Removal Can Favor the Use of Fe‐DFO‐N‐suc‐TFP Ester Over p‐NCS‐Bz‐DFO TE Wuensche, S Nauta, GAMS van Dongen, DJ Vugts Journal of Labelled Compounds and Radiopharmaceuticals, 2024 | | 2024 |
| Unlocking the full Potential of N-suc-DFO-mAbs for 89Zr-Immuno-PET: A new method on Mild Removal of Iron from Fe-DFO-N-suc-mAb Complexes T Wuensche, S Nauta, GAMS van Dongen, D Vugts Nuclear Medicine and Biology 126, 108738, 2023 | | 2023 |
| Visualization of brain targets with 89Zr‐immuno‐PET using a novel bispecific amyloid ß monoclonal antibody N Stergiou, T Wünsche, I Mes, M Schreurs, M Verlaan, E Kooijman, ... Alzheimer's & Dementia 17, e053052, 2021 | | 2021 |
| In vivo stable hg-197 (m) compounds, method for the production thereof and use thereof in nuclear medical diagnostics and endoradionuclide therapy (theranostics) H Pietzsch, M Walther, T Wünsche US Patent App. 17/159,968, 2021 | | 2021 |
| Zr-89-immuno-PET of a novel bispecific amyloid-beta monoclonal antibody reveals improved and high specific brain uptake N Stergiou, T Wuensche, I Mes, M Schreurs, M Verlaan, E Kooijman, ... Nuclear Medicine and Biology 96, S30-S31, 2021 | | 2021 |
| In vivo stable hg-197 (m) compounds, method for the production thereof and use thereof in nuclear medical diagnostics and endoradionuclide therapy (theranostics) HJ Pietzsch, M Walther, T Wünsche | | 2018 |
| Synthesis and evaluation of [C-11] propiverine as radiotracer for PET imaging of muscarinic acetylcholine receptors T Wuensche, JJ Bailey, M Wuest, F Wuest JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS 60, S42-S42, 2017 | | 2017 |
